(Q39400951)

11 September 2017

title

Angiotensin-I converting enzyme inhibitors suppress angiogenesis and growth of esophageal carcinoma xenografts (English)

1 reference

11 September 2017

1 reference

1 reference

Q Wang

1

1 reference

11 September 2017

X Lei

series ordinal

2

1 reference

11 September 2017

S Zhu

series ordinal

3

1 reference

11 September 2017

S Zhang

series ordinal

4

1 reference

11 September 2017

language of work or name

1 reference

6 February 2012

1 reference

Diseases of the Esophagus

11 September 2017

published in

1 reference

11 September 2017

volume

25

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

757-763

1 reference

Estimating the world cancer burden: Globocan 2000.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Oesophageal cancer composed of mixed histological types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Multiple management modalities in esophageal cancer: combined modality management approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Characterization of 21 newly established esophageal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2050.2011.01320.X

10.1111/J.1442-2050.2011.01320.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference